Optimal immunosuppressive clinical regimen in liver transplantation.
Farges
O
O
Hepato-biliary Surgery and Liver Transplantation Center, Paul Brousse Hospital, Villejuif, France.
Samuel
D
D
Bismuth
H
H
D000163:Acquired Immunodeficiency Syndrome / Q000401:mortality; D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002423:Cause of Death; D016572:Cyclosporine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000628:therapy; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D008107:Liver Diseases / Q000601:surgery; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine; D008775:Methylprednisolone